The outcome of treatment-refractory and/or relapsed pediatric T cell acute lymphoblastic leukemia (T-ALL) is extremely poor 1 , and the genetic basis for this is not well understood. Here we report comprehensive profiling of 121 cases of pediatric T-ALL using transcriptome and/or targeted capture sequencing, through which we identified new recurrent gene fusions involving SPI1 (STMN1-SPI1 and TCF7-SPI1). Cases positive for fusions involving SPI1 (encoding PU.1), accounting for 3.9% (7/181) of the examined pediatric T-ALL cases, showed a double-negative (DN; CD4 − CD8 − ) or CD8 + single-positive (SP) phenotype and had uniformly poor overall survival. These cases represent a subset of pediatric T-ALL distinguishable from the known T-ALL subsets 2 in terms of expression of genes involved in T cell precommitment, establishment of T cell identity, and post-b-selection maturation and with respect to mutational profile. PU.1 fusion proteins retained transcriptional activity and, when constitutively expressed in mouse stem/progenitor cells, induced cell proliferation and resulted in a maturation block. Our findings highlight a unique role of SPI1 fusions in high-risk pediatric T-ALL.
integration of Friend erythroleukemia virus (Spi1) 10, 11 , SPI1 is expressed in various hematopoietic compartments in which tightly regulated SPI1 expression is essential for the normal development of hematopoietic stem cells [12] [13] [14] [15] [16] [17] [18] [19] [20] . During T cell development, like other phase 1 genes involved in precommitment to the T cell lineage (such as LYL1, LMO2, GATA2, MEIS1, and BCL11A) 21 , SPI1 is expressed in prethymic progenitors and early T cell precursors (ETPs) 22 . SPI1 expression is then shut off and replaced by the expression of TCF7 and other phase 2 genes (such as NOTCH1, RUNX1, GATA3, TCF3 (E2A), and BCL11B) during the transition from CD44 + CD25 + (DN2) to CD44 + CD25 − (DN3) T cells, followed by the expression of phase 3 genes, such as ETS2, LEF1, and ID3 (refs. 21,23) .
SPI1-fusion-positive samples invariably showed markedly elevated SPI1 expression (Fig. 1c) , most likely reflecting high levels of fusion transcripts from the rearranged allele, whose expression is under the control of the heterologous promoter from the TCF7 or STMN1 gene; these transcripts were demonstrated to be highly expressed in fusion-positive samples (Supplementary Fig. 2 ). This scenario was suggested by the disproportionally high numbers of RNA-seq reads from 3′ SPI1 exons in comparison to 5′ SPI1 exons ( Supplementary Fig. 2 ) and was directly confirmed by the markedly increased number of breakpointcontaining reads for the SPI1 fusion found specifically in fusion-positive samples ( Supplementary Fig. 3 and Supplementary Table 4) .
Irrespective of the fusion partner, all predicted PU.1 fusion proteins retained the domain for DNA binding (ETS domain), but varying segments of the protein were missing from the C terminus 24 . To assess the transcriptional potential of the PU.1 fusion proteins, we performed luciferase assays in HeLa cells carrying a reporter containing the PU.1-responsive promoter sequence from CSF1R (encoding macrophage colony-stimulating factor (M-CSF) receptor) 25 . In comparison to empty vector, transfection with the STMN1-SPI1 and TCF7-SPI1 fusion constructs resulted in a marked increase (eight-to tenfold) in luciferase activity, and this increase was almost completely absent when the sequence encoding the DNA-binding ETS domain was deleted from SPI1 ( Fig. 2a and Supplementary  Fig. 4 ), suggesting that both PU.1 fusions retain the transcriptional activity inherent to PU.1. Next, we evaluated the effect of the SPI1 fusions on T cell proliferation. DN T cells from wild-type mice were transduced with constructs encoding SPI1 fusions or wild-type SPI1 together with GFP downstream of an IRES, and 3.0 × 10 3 GFP-positive transduced cells were subjected to in vitro cell culture to examine the effect of both SPI1 fusions on cell proliferation. Cells transduced to express wild-type SPI1 and the SPI1 fusions showed significantly higher proliferation rates than cells transduced with empty vector (P = 2.1 × 10 −2 for STMN1-SPI1, 1.8 × 10 −3 for TCF7-SPI1 type 1, and 1.3 × 10 −2 for TCF7-SPI1 type 2, Student's t test; Fig. 2b) . We also investigated the effects of SPI1 fusion on T cell development using a TSt4/DLL1 co-culture system 26, 27 in which mouse DN1 and DN2 thymocytes (Lin − CD44 + ) were transduced to express wild-type SPI1 or each SPI1 fusion and cultured on TSt4/DLL1 mouse stromal cells. As shown in Figure 2c -f, cells expressing STMN1-SPI1 and TCF7-SPI1 and those expressing wild-type SPI1 showed a differentiation block during DN T cell development, and there were reduced numbers of DP, SP (CD4 + or CD8 + ), and DN4 T cells in comparison to control cells, accompanied by an increase in the number of DN cells, especially immature DN T cells (DN1/DN2 cells). However, the effects of the STMN1-SPI1 fusion were milder than those of wild-type SPI1 and the TCF7-SPI1 fusion. To determine the in vivo effects of SPI1 fusion on T cell differentiation ( Supplementary  Fig. 5 ), mouse stem cells (CD105 + Sca-1 + ; long-term reconstituting hematopoietic stem cells (LTR-HSCs)) were transduced to express either wild-type SPI1 or the TCF7-SPI1 fusion and transplanted into lethally irradiated mice. The cells were analyzed for their differentiation potential within the thymus. In accordance with the in vitro analysis, recipients of cells expressing wild-type SPI1 and the TCF7-SPI1 fusion showed significantly increased numbers of DN T cells and reduced numbers of CD4 + and CD8 + SP T cells as compared to control mice, although the reduction in the number of CD4 + SP cells was not statistically significant in mice transplanted with cells expressing wild-type SPI1. Differential counts of DN T cells also showed trends similar to those found in the in vitro analysis, including increased numbers in immature DN fractions (DN1 and DN2) and reduced numbers in a more mature fraction (DN4). Moreover, the recipients of fusion-expressing cells exhibited a higher proportion of immature CD8 + SP T cells (CD4 − CD8 + CD24 + cells lacking expression of T cell receptor β (TCRβ); Supplementary Fig. 5 ).
To further characterize SPI1-fusion-positive T-ALL, we performed gene expression profiling of 123 individuals with T-ALL, including 2 additional fusion-positive cases. Using consecutive two-step unsupervised consensus clustering, we obtained five stable clusters (Fig. 3 and Supplementary Figs. 6 and 7) . Among these, four clusters largely recapitulated distinct T-ALL subtypes characterized in previous studies by an ETP expression profile, high TAL1 expression (TAL1 related; two clusters), and mutually exclusive expression of TLX1 and TLX3 (TLX related) ( Fig. 3 and Supplementary Figs. 6 and 7) 28, 29 . The TAL1-related cluster was further classified into two stable subclusters, which conform to TAL1-related type A (TAL1-RA) and TAL1-related type B (TAL1-RB) in the previous literature 29 and SPI1-fusion-negative (n = 116) cases; normalized read counts mapping to SPI1 exons 1-5 are plotted. The P value was calculated using the Wilcoxon rank-sum test. The mean and 25th and 75th percentiles are represented in the box plots by the midline and box edges, respectively, and whiskers extend to 1.5 times the interquartile range. Dots represent each read count of SPI1. l e t t e r s l e t t e r s immunophenotypic characteristics. However, the remaining cluster was newly identified and consisted exclusively of the seven SPI1-fusion-positive cases. In terms of their characteristic gene expression pattern, SPI1-fusion-positive cases showed a phenotype mimicking that of normal DN3 or DN4 T cells 30 , which was distinct from the phenotype shown by cases from other clusters ( Supplementary  Fig. 8 ). In comparison to ETP-ALL cases, individuals who were positive for SPI1 fusion typically showed reduced expression of the phase 1-specific transcription factor genes implicated in early T cell development 31 . An exception to this was aberrant expression of SPI1 and PU.1-regulated genes (MEF2C and HHEX) [32] [33] [34] , which may be ascribed to the SPI1 gene fusions. Of interest in this regard was aberrantly elevated expression of FLT3 and KIT in the SPI1 fusion cluster; expression of these genes has also been reported to be regulated by PU.1 ( Supplementary Figs. 9 and 10) 35, 36 . In contrast, ETP-ALL cases typically lacked expression of phase 2-and phase 3-related genes, which were largely upregulated in SPI1-fusion-positive cases. Unlike TLX-related, TAL1-RA and TAL1-RB cases, which are largely thought to have phenotypes conforming to those of DP T cells, none of the SPI1-fusion-positive cases showed overexpression of HOXA9, TLX1, TLX3, and TAL1 (Supplementary Fig. 8 ).
Genetic alterations in the 121 T-ALL cases, including 7 SPI1-fusionpositive cases, were also investigated using targeted capture sequencing of 158 genes commonly mutated in pediatric ALL (Online Methods), which were determined by analysis of whole-exome sequencing data from the Therapeutically Applicable Research to Generate Effective Wild-type cells constructs, with corresponding P values displayed (Student's t-test). *P < 0.05, **P < 0.01, ***P < 0.001; N.S., not significant. Tables 5-7 ). In line with previous reports 2, [37] [38] [39] , NOTCH1 (74%) and CDKN2A (73%) were by far the most frequently affected genes in T-ALL, although the frequency of CDKN2A lesions was characteristically lower in ETP-ALL than in other T-ALL subtypes (P = 1.8 × 10 −9 , Fisher's exact test) ( Supplementary  Fig. 9 ). Other frequently mutated genes (with mutations in >10% of cases) included PHF6, FBXW7, PTEN, DNM2, USP7, NRAS, JAK3, WT1, and RUNX1 (Fig. 4a) , which, except for USP7, have previously been reported as mutated in T-ALL 8, 31, [40] [41] [42] [43] [44] [45] [46] [47] . The distribution of these genetic alterations differed substantially among the T-ALL subtypes, corresponding to a unique mutational profile for each subtype (Fig. 4b) .
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As shown in previous reports 31, 44 SPI1  TAL1  TLX1  TLX3  HOXA9  SPI1  TAL1  TLX1  MLL  NOTCH1  FBXW7  GATA3  RUNX1  ETV6  TCF7  LEF1  BCL11B  WT1  MYB  CREBBP  IKZF1  IKZF2  NRAS  KRAS  NF1  IL7R  JAK1  JAK3  STAT5A  STAT5B  PTEN  USP7  PIK3R1  AKT1  MTOR  BRAF  MYC  CDKN2A  CCND3  RB1  TP53  PHF6  EZH2  EED  SUZ12  EP300  SETD2  DNM2  KDM6A  KMT2A  KMT2C  CTCF  MED12  CIC  ASXL2  BCOR  CNOT1  CNOT3 l e t t e r s epigenetic regulators were also found in TLX-related T-ALL, in which especially high frequencies of PHF6 and WT1 mutations were among the unique mutational features. The TAL1-RA and TAL1-RB subtypes 29 were distinguished from each other not only by their unique gene expression profiles but also by gene mutations: TAL1-RA was characterized by a paucity of the mutations commonly found in TAL1-RB, with the exception of frequent PTEN and USP7 abnormalities. Frequent mutations in USP7, which is involved in PTEN deubiquitination 48 , were newly identified in this particular subtype of T-ALL. In contrast, TAL1-RB showed frequent mutations in NOTCH1 and/or FBXW7, transcription factors, RAS pathway components, and epigenetic regulators. Although the small number of SPI1-fusion-positive T-ALL cases precluded accurate evaluation of this subtype, the analyzed cases shared several genetic abnormalities with other T-ALL subtypes 2,37,49 , such as frequent NOTCH1 and/or FBXW7 mutation (6 of 7 cases) and CDKN2A deletion (6 of 7 cases), whereas other mutations commonly found in the other T-ALL subtypes did not seem to occur frequently in the SPI1 fusion subtype; the exception was alterations to RAS pathway genes, which were found in 4 cases (57%) with SPI1 fusion (Supplementary Fig. 9 ). Finally, we evaluated the effects of SPI1 fusions on the clinical outcomes of individuals with T-ALL (Fig. 5) . When compared to SPI1-fusion-negative cases, SPI1-fusion-positive cases showed significantly shorter overall survival, with a median survival time of 2.2 years (hazard ratio (HR) = 6.05, 95% confidence interval (95% CI) = 2.4−15.1, log-rank P = 1.12 × 10 −8 ); six of the seven individuals died within 3 years of diagnosis from early relapse (Fig. 5a,d) . The survival time of individuals with SPI1 fusions was shorter than that of individuals with other fusions or in other clusters (log-rank P = 5.12 × 10 −4 and 
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VOLUME 49 | NUMBER 8 | AUGUST 2017 Nature GeNetics l e t t e r s P = 3.17 × 10 −5 , respectively) (Fig. 5b,c) . In multivariate analysis, SPI1 fusion status was shown to be an independent predictor of survival in pediatric T-ALL (Table 1) , indicating a possible link between SPI1 fusions and an aggressive disease phenotype. SPI1 is required to be downregulated in the DN3 stage of T cell development for normal thymocyte differentiation to occur 50 . Constitutive SPI1 expression in fetal thymocyte organ culture leads to a block in development at the DN3 stage and favors differentiation into macrophage 51 . In SPI1-fusion-positive cells, expression of functionally active PU.1 from the fusion gene is thought to be maintained during the DN2-DN3 (refs. 21,52) and DN-DP 52 transitions, at which points TCF7 and STMN1 are expressed, respectively. In fact, RNA-seq data from these fusion-positive samples confirmed markedly elevated expression of full-length TCF7 and STMN1 transcripts together with transcripts fused with SPI1 sequences, whereas transcription from the wild-type SPI1 allele was silenced (Supplementary Fig. 2 ). In the context of this finding, it is interesting that a recent report described a T-ALL case in which SPI1 was translocated to the BCL11B locus and overexpressed from a promoter of BCL11B, a gene expressed at the DN2 and DN3 stages (Supplementary Fig. 11 ) 33 . Therefore, it is postulated that ectopic SPI1 expression during the DN2-DN3 transition may cause a differentiation block in the DN3 stage, contributing to T cell leukemogenesis. In accordance with this hypothesis, SPI1-fusion-positive leukemic cells showed a DN or CD8 + SP phenotype and a gene expression profile that conformed to that of DN3 and DN4 T cells, and these cells are therefore thought to be more immature than those from the TAL1-and TLX-related subtypes but more differentiated than those from the ETP subtype (Supplementary Fig. 9 ). In support of this notion, upregulated SPI1 expression in mice lacking the upstream regulatory element that normally suppresses SPI1 expression in T cells also caused an impaired transition to the DN3 stage and even resulted in a high frequency of T cell lymphoma 50, 53 .
In conclusion, we have described new recurrent fusions involving SPI1 in pediatric T-ALL. Exhibiting unique cytological and gene expression profiles, cases of SPI1-fusion-positive T-ALL had a uniformly dismal clinical outcome. To the best of our knowledge, these are the first genetic lesions associated with a very poor prognosis in pediatric T-ALL, although their impact on survival needs to be confirmed in additional cases. T-ALL in patients with SPI1 fusions seems to be incurable with current standard chemotherapy, which underscores the importance of detecting this subset of patients so that they may receive more intensive or alternative therapies. In this regard, the RAS pathway mutations and aberrant expression of FLT3 and KIT associated with SPI1-fusionpositive T-ALL are of interest, as they could potentially be targeted for therapeutic benefit, although further studies are warranted.
URLs. Genomon2, http://genomon.readthedocs.io/ja/latest/index. html; Integrative Genomics Viewer (IGV), https://www.broadinstitute.org/igv/; Genomon2.3.0, https://github.com/Genomon-Project/ GenomonPipeline.
MeTHODS
Methods, including statements of data availability and any associated accession codes and references, are available in the online version of the paper. 
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We gratefully acknowledge the TCGA Consortium and all its members for making their invaluable data publically available. The results published here are in whole or part based upon data generated by the Therapeutically Applicable Research to Generate Effective Treatment (TARGET) initiative managed by the NCI. Information about TARGET can be found at http://ocg.cancer.gov/programs/target. We are also grateful to M. Matsumura, N. Hoshino, K. Yin, F. Saito, Y. Mori, N. Mizota, and M. Nakamura for their excellent technical assistance. We also wish to express our appreciation to M. Double-negative thymocyte culture. We purified lineage marker (Gr-1, Mac-1, Ter-119, B220, CD4, CD8α, γδTCR, CD3, CD11c, and NK1.1) − CD44 + CD25 − DN1 and CD44 + CD25 + DN2 cells from a mouse thymus and transduced them with the indicated retroviruses on TSt-4/DLL1 stromal cells supplemented with 20 ng/ml stem cell factor (SCF), IL-7, and Flt3L. Three days following transduction, we sorted transduced cells expressing GFP, plated them on TSt-4/DLL1 stromal cells, and monitored their growth in the presence of 20 ng/ml SCF, IL-7, and Flt3L in triplicate; their growth was monitored at days 7, 14, and 21. To evaluate the impact of transduced genes on the differentiation of DN1 or DN2 cells, sorted GFP + cells were cultured on TSt-4/DLL1 stromal cells in the presence of 1 ng/ml SCF, IL-7, and Flt3L for 7 d, stained with either anti-CD45.2, anti-CD4, and anti-CD8 antibodies or anti-CD45.2, lineage-marker mixture, anti-CD25, and anti-CD44 antibodies, and subjected to flow cytometric analyses. The fraction of GFP-positive cells is shown in Supplementary Figure 12 .
Isolation of adult LTR-HSCs. Following previously described methods 62, 63 , hematopoietic progenitors were collected from female C57BL/6 mice aged 6-10 weeks 4 d after intraperitoneal administration of 150 mg/kg 5-fluorouracil (5-FU) and were isolated using lymphoprep (Axis-Shield). MSCV-IRES-GFP vector and pMYs vector encoding TCF7-SPI1 or wild-type SPI1 were transfected using polyethylenimine into Plat-E cells, an ecotropic packaging cell line. Supernatants containing high titers of retrovirus were collected at 48 and 72 h, concentrated using the Retro-X Concentrator (TAKARA-Clontech), and used to infect the isolated LTR-HSCs. Infection was performed on a Retronectincoated plate with 4 µg/ml protamine. Hematopoietic progenitors were cultured overnight in αMEM supplemented with 20% FCS and 50 ng/ml each of mouse SCF (R&D Systems, 455-MC-010), human IL-6 (PEPROTECH, 200-06), human FLT3 ligand (PEPROTECH, 250-31L), and human thrombopoietin. On the second day, cells were infected with retrovirus particles in αMEM supplemented with FCS and the same cytokines using 24-well dishes coated according to the manufacturer's recommendations with Retronectin. 60 h after infection with the retrovirus, LTR-HSCs were transplanted into C57BL/6 male mice aged 6-10 weeks that received myeloablative conditioning with 9.5 Gy of total-body irradiation 6 h before bone marrow transplantation. The mice had access ad libitum to drinking water containing 1 mg/ml neomycin trisulfate salt hydrate (Sigma) and 100 U/ml polymyxin B sulfate salt (Sigma). Samples from the thymus were stained using a five-or six-color combination of antibodies. Data were acquired on a BD LSRFORTESSA (Becton Dickinson) and analyzed using FACS DIVA software. The following antibodies were purchased from BioLegend and eBioscience: PE anti-mouse CD19 (1D3, 553786), Ly-6G/Ly-6C (Gr-1) (RB6-8C5, 108407), TER-119/erythroid cells (TER-119, 116208), NK-1.1 (PK136, 557391), CD11b (M1/70, 557397), and CD45R/B220 (RA3-6B2, 553089). The fraction of GFP-positive cells is shown in Supplementary  Figure 13 . Experiments were performed in a specific-pathogen-free unit in the vivarium of Tokyo Medical and Dental University. Experimental and animal care protocols were approved by the Tokyo Medical and Dental University animal care and use committee (protocol number 017012A).
Expression array analysis in normal T cell development. For the analysis of selected gene expression profiling in normal T cell development, public expression data were used. Replicate data in series matrix files (RMA-normalized processed data) were converted to log 2 (mean values).
Data availability. All sequencing data that support the findings of this study have been deposited in the DNA Data Bank of Japan (DDBJ) and are accessible through DDBJ accession number JGAS00000000090. The TARGET data used for this analysis are available from dbGaP (accession number phs000464). For the analysis of selected gene expression profiles in normal T cell development, public expression data submitted under GEO accession GSE22601 (Affymetrix Human Genome U133A Array) were used. All other relevant data are available from the corresponding authors upon reasonable request.
